[目的]探讨前列腺癌（PCa）患者血清腺激肽释放酶2（human kallikrein 2,hK2）检测的临床意义。[方法]采用酶联免疫吸附试验（ELISA）和放射免疫分析法（RIA）分别检测30例PCa、30例前列腺增生（BPH）患者和30名健康人血清hK2和前列腺特异性抗原（PSA）的水平。并随访12例行根治性前列腺全切术后PCa患者hK2水平。[结果]PCa组hK2水平为78.8±25.2ng/L,明显高于BPH组（25.4±6.28ng/L）和健康组（24.1±4.16ng/L）,差异有统计学意义（P〈0.05）;hK2检测PCa的敏感度、特异性、准确率分别为63.3%,90.0%,76.6%;血清hK2诊断PCa的ROC曲线下面积为0.767（95%CI：0.642-0.891）;12例PCa患者手术前和手术后hK2比较差异有统计学意义（81.5±24.8ng/L vs 38.4±13.5ng/L,P〈0.001）。[结论]血清hk2诊断PCa,可能可以提高其特异性,减少不必要的活检率,有望成为新的PCa检测指标预测高危人群。
Objective To examine long term efficacy of percutaneous transluminal coronary angioplasty (PTCA),coronary stenting and to assess the factors affecting its efficacy Methods A total of 790 patients who underwent successful PTCA and PTCA+stent in this hospital were followed by direct interview or letter The rate of follow up was 84 2% and the period of follow up was 0 9-12 7 (3 5±2 4) years Results During follow up, 4 (0 5%) patients died, 22 (2 8%) had nonfatal acute myocardial infarction, 10 (1 3%) had coronary artery bypass surgery, and 98 (12 4%) had repeat PTCA The rate of recurrent angina pectoris was 31 1% The cardiac event free survival rate calculated by the Kaplan Meier method was 88 2% at 1 year and 80 6% at 12 7 years Cox regression analysis showed that there was a positive correlation between AMI history, stent implantation and the risk of cardiac events, and there was a negative correlation between the number of diseased arteries and the risk of cardiac events Compared to the PTCA group, patients with PTCA+stent had significantly lower rates of total cardiac events Conclusion The long term efficacy of PTCA, especially PTCA + stent in Chinese patients was very satisfactory, suggesting that PTCA+stent therapy should be the major treatment for revascularization in patients with coronary heart disease
